ICE Bioscience Posters

Download

Antibody-drug conjugates (ADCs), combining the precision of antibodies with the potency of cytotoxic drugs, represent a promising anticancer therapy. However, current ADCs face significant challenges, including non-responsive cancers and rapid patient relapse, primarily due to tumor heterogeneity and drug resistance. To address these issues, dual-payload ADCs have emerged as a novel strategy, delivering two cytotoxic agents to enhance efficacy through synergistic effects, mitigate resistance, and offer flexible dosing. Despite their potential, the development of dual-payload ADCs remains complex. Cell panel-based studies and drug-resistant cell lines provide powerful tools to explore effective dual-payload ADCs by evaluating drug combination synergies and elucidating resistance mechanisms.